2 results
Approved WMOWill not start
Part I of this study is designed to identify the recommended phase 2 dose of the combination regimen of galunisertib/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant colorectal carcinoma. Part II is designed to…
Approved WMORecruiting
This study has been transitioned to CTIS with ID 2024-518980-37-00 check the CTIS register for the current data. With this clinical study, we aim to gain more information about the pharmacological characteristics, safety profile, tolerability and…